# 2026-19400: DEA Bans Five Weird Hallucinogens: Tryptamine Trip Ends 2026-19400, Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2026-09-23, effective Comments must be submitted electronically or postmarked on or before October 23, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.; PRIA reads it as touching household money (as of 2026-09-30). - Canonical: https://policyrisk.com/federal-register/2026-19400 - As of: 2026-09-30 - Plain-text twin of the page above; the HTML and this file carry the same facts. ## Facts - Document number: 2026-19400 - Title: Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I - Type: Proposed Rule - Agencies: Justice Department; Drug Enforcement Administration - Citation: 91 FR 60338 - Published: 2026-09-23 - Effective: Comments must be submitted electronically or postmarked on or before October 23, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period. - Comments close: 2026-10-23 - Significant: no - Touches household money: yes - Regulation identifier numbers: none - Last updated: 2026-09-30 ## In one line DEA Bans Five Weird Hallucinogens: Tryptamine Trip Ends ## Summary The Drug Enforcement Administration wants to put five specific hallucinogenic drugs into Schedule I, meaning they’ll be treated as illegal with strict rules. This affects anyone who makes, sells, studies, or owns these drugs, adding serious legal consequences. You have until October 23, 2026, to share your thoughts or ask for a hearing before the rule might become official. ## Abstract The Drug Enforcement Administration proposes placing five tryptamine hallucinogens, 4-hydroxy-N,N-diisopropyltryptamine (other names: 4-OH-DiPT; 3-(2-(diisopropylamino)ethyl)-1H-indol-4- ol), 5-methoxy-alpha-methyltryptamine (other names: 5-MeO-AMT; 1-(5- methoxy-1H-indol-3-yl)propan-2-amine), 5-methoxy-N-methyl-N- isopropyltryptamine (other names: 5-MeO-MiPT; N-(2-(5-methoxy-1H-indol- 3-yl)ethyl)-N-methylpropan-2-amine), 5-methoxy-N,N-diethyltryptamine (other names: 5-MeO-DET; N,N-diethyl-2-(5-methoxy-1H-indol-3- yl)ethanamine), and N,N-diisopropyltryptamine (other names: DiPT; N-(2- (1H-indol-3-yl)ethyl)-N-isopropylpropan-2-amine), including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specific tryptamine hallucinogens. ## Effects PRIA read - Five tryptamines moved to Schedule I: cost, high. The Drug Enforcement Administration proposes to place 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT into Schedule I. If finalized, these substances would be treated as illegal under the Controlled Substances Act and subject to the civil, administrative, and criminal sanctions that apply to… - DEA registration required to handle substances: cost, medium. Anyone who manufactures, distributes, imports, exports, researches, analyzes, or possesses these five tryptamines would need to be registered with DEA under the Controlled Substances Act. The rule says people currently handling them who are not registered must apply for registration and may not con… - 90-day rule to continue some research after scheduling: mixed, medium. If the final rule is effectuated, a person already registered to conduct research with another Schedule I controlled substance may continue research on these five tryptamines only if they submit a completed application or modification to conduct research with them within 90 calendar days after the… - Surrender or transfer stock before effective date: cost, medium. People who are unwilling or unable to obtain a Schedule I registration must surrender or transfer all quantities of these substances to a DEA-registered person before the effective date of the final scheduling action, and dispose of them according to applicable law and 21 CFR part 1317. That means… - Retail sales banned; unauthorized possession illegal: cost, high. The Controlled Substances Act does not allow retail sales of Schedule I drugs to the general public. Possession of any quantity of these substances without authorization under the CSA would be unlawful and could lead to prosecution. - Schedule I security and storage rules apply: cost, medium. If these tryptamines are placed in Schedule I, they would be subject to Schedule I security requirements and must be handled and stored in accordance with the Controlled Substances Act and implementing regulations. That will require entities that keep these substances to meet Schedule I physical se… ## Related documents - [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09 - [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20 - [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24 - [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19 - [2026-20749](https://policyrisk.com/federal-register/2026-20749): Vladimir Romaniv, P.A.; Decision and Order, 2026-10-09 - [2026-20750](https://policyrisk.com/federal-register/2026-20750): L Krenk DBA Maui Clinic Pharmacy; Decision and Order, 2026-10-09 ## Sources - [2026-19400 on federalregister.gov](https://www.federalregister.gov/documents/2026/09/23/2026-19400/schedules-of-controlled-substances-placement-of-4-hydroxy-nn-diisopropyltryptamine-4-oh-dipt) - [2026-19400 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-09-23/pdf/2026-19400.pdf) ## Related - [Previous: 2026-19370, Part 572; Anthropomorphic Test Devices; Test Device for Human Occupant Restrain…](https://policyrisk.com/federal-register/2026-19370) - [Next: 2026-19411, Airworthiness Directives; Textron Aviation, Inc. (Type Certificate Previously H…](https://policyrisk.com/federal-register/2026-19411) - [All Federal Register documents](https://policyrisk.com/federal-register) Source: PRIA, https://policyrisk.com/federal-register/2026-19400 (as of 2026-09-30).